Nicole Sendey - Kane Biotech Investor Adviser
| KNBIF Stock | USD 0.08 0.0003 0.39% |
Insider
Nicole Sendey is Investor Adviser of Kane Biotech
| Phone | 204 453 1301 |
| Web | https://kanebiotech.com |
Kane Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3915) % which means that it has lost $0.3915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.968) %, meaning that it generated substantial loss on money invested by shareholders. Kane Biotech's management efficiency ratios could be used to measure how well Kane Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | INSIDER Age | ||
| Mireille MSc | Pharming Group NV | 55 | |
| Jeroen Wakkerman | Pharming Group NV | 54 | |
| Ruud Outersterp | Pharming Group NV | 59 | |
| Stephen Toor | Pharming Group NV | 52 | |
| Susanne Embleton | Pharming Group NV | N/A | |
| MBA MD | Pharming Group NV | 63 | |
| Anurag Relan | Pharming Group NV | 51 | |
Management Performance
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 |
Kane Biotech Leadership Team
Elected by the shareholders, the Kane Biotech's board of directors comprises two types of representatives: Kane Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kane. The board's role is to monitor Kane Biotech's management team and ensure that shareholders' interests are well served. Kane Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kane Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Cole, Pres Inc | ||
| Wendy Nachtigall, Director Marketing | ||
| Mark AhrensTownsend, President CEO | ||
| Gregory Schultz, Chief Board | ||
| Lorne Gorber, Investor Relations | ||
| Marc Edwards, Interim CEO, Director | ||
| Ray Dupuis, Chief Officer | ||
| Nicole Sendey, Investor Adviser | ||
| Lori Christofalos, VP Compliance |
Kane Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Kane Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Shares Owned By Insiders | 26.82 % | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.